Literature DB >> 19886711

Ovarian cancer update: lessons from morphology, molecules, and mice.

Kathleen R Cho1.   

Abstract

Ovarian carcinomas are a heterogeneous group of neoplasms. Pathologists currently employ a morphology-based classification system to divide ovarian carcinomas into major subgroups based on degree (tumor grade) and type of differentiation (eg, serous, endometrioid, clear cell, or mucinous). Molecular studies have shown that specific genetic defects are likely to be present in certain histologic types of ovarian carcinomas and unlikely to be present in others. Within the serous and endometrioid carcinomas, the molecular defects in low-grade versus high-grade tumors also appear to be largely distinct. Recently, mouse models of ovarian carcinoma have been developed that recapitulate many of the morphologic features and biologic behavior of selected subtypes of ovarian cancer. It is expected that these mouse models will yield new insights into ovarian cancer pathogenesis and prove useful for preclinical testing of novel strategies for ovarian cancer treatment.

Entities:  

Mesh:

Year:  2009        PMID: 19886711      PMCID: PMC2774913          DOI: 10.5858/133.11.1775

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  33 in total

Review 1.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

2.  HOXB7: a key factor for tumor-associated angiogenic switch.

Authors:  A Carè; F Felicetti; E Meccia; L Bottero; M Parenza; A Stoppacciaro; C Peschle; M P Colombo
Journal:  Cancer Res       Date:  2001-09-01       Impact factor: 12.701

3.  Diverse tumorigenic pathways in ovarian serous carcinoma.

Authors:  Gad Singer; Robert J Kurman; Hsueh-Wei Chang; Sarah K R Cho; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

4.  Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.

Authors:  Robert E Bristow; Rafael S Tomacruz; Deborah K Armstrong; Edward L Trimble; F J Montz
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

5.  Grading ovarian serous carcinoma using a two-tier system.

Authors:  Anais Malpica; Michael T Deavers; Karen Lu; Diane C Bodurka; Edward N Atkinson; David M Gershenson; Elvio G Silva
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

Review 6.  The biology and clinical relevance of the PTEN tumor suppressor pathway.

Authors:  Isabelle Sansal; William R Sellers
Journal:  J Clin Oncol       Date:  2004-07-15       Impact factor: 44.544

Review 7.  Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

Authors:  Ie-Ming Shih; Robert J Kurman
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

8.  Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.

Authors:  Mary L Gemignani; Alan C Schlaerth; Faina Bogomolniy; Richard R Barakat; Oscar Lin; Robert Soslow; Ennapandam Venkatraman; Jeff Boyd
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

9.  Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases.

Authors:  Ann E Smith Sehdev; Paul S Sehdev; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2003-06       Impact factor: 6.394

10.  Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.

Authors:  Donald R Schwartz; Sharon L R Kardia; Kerby A Shedden; Rork Kuick; George Michailidis; Jeremy M G Taylor; David E Misek; Rong Wu; Yali Zhai; Danielle M Darrah; Heather Reed; Lora H Ellenson; Thomas J Giordano; Eric R Fearon; Samir M Hanash; Kathleen R Cho
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  25 in total

1.  Primary mucinous cystadenocarcinoma of the pelvic retroperitoneum in a male.

Authors:  Andrew K Williams; Shawna L Boyle; Susanne M Chan; Carlos H Martinez; Chen Lu; Joseph L Chin
Journal:  Can Urol Assoc J       Date:  2010-12       Impact factor: 1.862

Review 2.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

3.  PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation.

Authors:  Angela Russo; Austin A Czarnecki; Matthew Dean; Dimple A Modi; Daniel D Lantvit; Laura Hardy; Seth Baligod; David A Davis; Jian-Jun Wei; Joanna E Burdette
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

4.  Inactivation of TRP53, PTEN, RB1, and/or CDH1 in the ovarian surface epithelium induces ovarian cancer transformation and metastasis.

Authors:  Mingxin Shi; Allison E Whorton; Nikola Sekulovski; Marilène Paquet; James A MacLean; Yurong Song; Terry Van Dyke; Kanako Hayashi
Journal:  Biol Reprod       Date:  2020-04-24       Impact factor: 4.285

5.  PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression.

Authors:  Pradeep S Tanwar; Tomoko Kaneko-Tarui; Ho-Joon Lee; Lihua Zhang; Jose M Teixeira
Journal:  Carcinogenesis       Date:  2012-12-31       Impact factor: 4.944

Review 6.  [Preneoplasias of ovarian carcinoma: biological and clinical aspects of different pathways of tumorigenesis].

Authors:  A Staebler
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

7.  Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.

Authors:  Hanqing Liu; Fang Xiao; Ilya G Serebriiskii; Shane W O'Brien; Marisa A Maglaty; Igor Astsaturov; Samuel Litwin; Lainie P Martin; David A Proia; Erica A Golemis; Denise C Connolly
Journal:  Clin Cancer Res       Date:  2013-07-30       Impact factor: 12.531

8.  WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.

Authors:  Shin Yoshioka; Mandy L King; Sophia Ran; Hiroshi Okuda; James A MacLean; Mary E McAsey; Norihiro Sugino; Laurent Brard; Kounosuke Watabe; Kanako Hayashi
Journal:  Mol Cancer Res       Date:  2012-01-09       Impact factor: 5.852

9.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

10.  The roles of parafibromin expression in ovarian epithelial carcinomas: a marker for differentiation and prognosis and a target for gene therapy.

Authors:  Dao-Fu Shen; Xin Liu; Xue-Feng Yang; Lei Fang; Yang Gao; Shuang Zhao; Ji-Cheng Wu; Shuai Shi; Jun-Jun Li; Xiang-Xuan Zhao; Wen-Feng Gou; Hua-Chuan Zheng
Journal:  Tumour Biol       Date:  2015-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.